Kairos Pharma's ENV-105 combination extends median progression-free survival to 17.7 months in Phase 2 prostate cancer trial
Bitget2026/11/03 16:45- Kairos Pharma will present interim ENV-105 efficacy results today at the 11th International Conference on Cancer Research & Drug Development in Houston.
- Phase 2 results showed ENV-105 with apalutamide significantly delayed disease progression versus apalutamide alone in metastatic castration-resistant prostate cancer.
- The trial will now focus on first-line therapy following enzalutamide, expanding enrollment to assess treatment resistance.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lithium-For-Earth Raises KRW 1.32 Billion in Private Placement
Anthropic "accidentally" leaks IPO documents! Plans to raise $69.3 billion, valuation drops from 2 trillion to 1.3 trillion
Anthropic mistakenly published and then withdrew a prospectus for a planned $69.3 billion fundraising, with its valuation dropping from a peak of $2 trillion to between $1.1 trillion and $1.3 trillion.
Subaru Publishes Transcript of First-Half FYE 2027 Financial Results Presentation
Citi: Occidental Petroleum (OXY.US) Q3 cash flow surpasses expectations, accelerated debt repayment cannot hide concerns over Q4 output
Citi published a research report maintaining Occidental Petroleum's "Neutral" rating, with a target price of $65.
Crypto prices
More
